---
schema_version: "secwatch.filing_event.v1"
accession: "0001459839-23-000102"
form_type: "8-K"
ticker: "SIBN"
cik: "0001459839"
company_name: "SI-BONE, Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T19:38:39.971870+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# SI-BONE reports Q3 2023 record revenue of $34.0M (+29% YoY); raises FY23 guidance to $136-137M

## Summary
- Q3 revenue $34.0M (+29% YoY); US revenue $32.3M (+31% YoY).
- Net loss improved to $10.0M ($0.25/sh) from $14.2M ($0.41/sh) YoY.
- Adjusted EBITDA loss improved 44% to -$3.9M.
- Raised fiscal 2023 revenue guidance to $136M-$137M from $132M-$134M.
- Over 1,040 US active surgeons (+30% YoY); 90,000 procedures worldwide.

## SEC filing metadata
- accession: 0001459839-23-000102
- form_type: 8-K
- ticker: SIBN
- cik: 0001459839
- company_name: SI-BONE, Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1459839/000145983923000102/0001459839-23-000102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1459839/000145983923000102/sibn-20231106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001459839-23-000102
- JSON: https://secwatch.observer/filing/0001459839-23-000102.json
- Plain text: https://secwatch.observer/filing/0001459839-23-000102.txt

## Key facts
- Earnings Releases
  SI-BONE, Inc. reported the quarter ended September 30, 2023 results: revenue $34.0 million, net income $10.0 million, or $0.25 per diluted share, EPS $0.25 per diluted share. Guidance raised.
  - Period: the quarter ended September 30, 2023
  - Revenue: $34.0 million
  - Net income: $10.0 million, or $0.25 per diluted share
  - EPS: $0.25 per diluted share
  - Guidance: raised
  - Result: reported results
  source text: disorders of the sacropelvic anatomy, today reported financial results for the quarter ended September 30, 2023. Recent Financial Highlights • Record worldwide revenue of $34.0 million for the third quarter 2023, representing approximately 29% growth over the corresponding period in 2022 • Record U.S. revenue of $32.3 million for the third quarter 2023,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1459839/000145983923000102/0001459839-23-000102-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.